Summary
Gonadotropin-releasing hormone analogs (GnRH-A) have been added to the armentarium in the therapy of hormone-dependent breast cancer in premenopausal women. The effect of chronic GnRH-A-treatment in premenopausal women is based on the suppression of the hypothalamus-pituitary-ovarian axis and the reduction of sex-steroid serum levels. In addition, a number of experimental and clinical data have been accumulated indicating a direct action of GnRH-A on breast cancer cells and tissue. In this study we analyzed 235 human breast cancer biopsies for specific GnRH-A-binding. We demonstrate high affinity GnRH-A binding sites in human breast cancer tissues. The evaluation of clinical data showed no correlation of the level of GnRH-A-binding with classical tumor parameters.
Article PDF
Avoid common mistakes on your manuscript.
References
Kaufmann M: Zoladex in treatment of premenopausal metastatic breast cancer patients. Hormone Res 32 (suppl 1): 202–205, 1989
Klijn JGM, De Jong FH, Lamberts SWJ, Blankenstein MA: LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873, 1985
Nicholson RI, Walker KJ, McClelland RA, Dixon A, Robertson RI, Blamey RW: Zoladex plus tamoxifen versus zoladex alone in pre- and peri-menopausal metastatic breast cancer. J Steroid Biochem Molec Biol 37: 989–995, 1990
Kovacs M, Mezö I, Seprödi J, Csernus V, Teplan I, Flerko B: Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system. Peptides 10: 925–931, 1989
Rabin D, McNeil LW: Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. J Clin Endocrinol Metab 51: 873–876, 1980
Crighton IL, Dowsett M, Lal A, Smith IE: Use of luteinizing hormone-releasing hormone agonist (leuprolin) in advanced post-menopausal breast cancer: clinical and endocrine effects. Br J Cancer 60: 644–648, 1989
Waxmann JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA: The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15: 171–173, 1985
Plowman PN, Nicholson RI, Walker KJ: Remission of postmenopausal breast cancer during treatment with the luteinising hormone-releasing hormone agonist ICI 118630. Br J Cancer 54: 903–909, 1986
Schwartz L, Guiochet N, Keiling R: Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer. Cancer 62: 2498–2500, 1988
Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV: Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4: 521–528, 1989
Srkalovic G, Wittliff JL, Schally AV: Detection and partial characterization of receptors for [D-Trp-6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50: 1841–1846, 1990
Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R: Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25: 215–221, 1989
Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425–432, 1987
Fekete M, Bajusz S, Groot K, Csernus VJ, Schally AV: Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor binding ability to rat pituitary and human breast cancer membranes. Endocrinology 124: 946–955, 1989
Kiesel L, Kaufmann M, Haeseler F, Klinga K, von Holst T, Schmidt W, Runnebaum B: GnRH-Rezeptoren im menschlichen Mammakarzinomgewebe. Geburtsh Frauenheilk 48: 420–424, 1988
Vincze B, Palyi I, Daubner D, Kremmer T, Szamel I, Bodrogi I, Sugar J, Seprödi J, Mezö I, Teplan I: Influence of luteinizing hormone-releasing hormone agonists on mammary carcinoma cell lines and their xenografts. J Steroid Biochem Molec Biol 38: 119–126, 1991
Srkalovic G, Szende B, Redding TW, Groot K, Schally AV: Receptors for D-trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med 192: 209–218, 1989
Blankenstein MA, Henkelman MS, Klijn JGM: Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21: 1493–1499, 1985
Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231–233, 1985
Mullen P, Scott WN, Miller WR: Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63: 930–932, 1991
Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV: Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86: 1648–1651, 1989
Szende B, Zalatnai A, Schally AV: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 86: 1643–1647, 1989
Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV: Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LHRH and somatostatin. Breast Cancer Res Treat 14: 307–314, 1989
Keri G, Balogh A, Szöke B, Teplan I, Csuka O: Gonadoptropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line. Tumor Biol 12: 61–67, 1991
Kiesel L, Sandow J, Bertgres K, Jerabek-Sandow G, Trabant H, Runnebaum B: Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis. J Clin Endocrinol Metab 68: 1167–1173, 1989
Greenwood FC, Hunter WH, Glower JS: The preparation of131 I labelled growth hormone of high specific radioactivity. Biochemistry 89: 114–123, 1963
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976
Scatchard G: The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 51: 660–672, 1949
Chamness GC, McGuire WL: Scatchard plots: common errors in correction and interpretation. Steroids 26: 538–542, 1975
Eidne KA, Flanagan CA, Millar RP: Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229: 989–991, 1985
Williamson DF, Parker RA, Kendrick JS: The Box Plot: a simple visual method to interpret data. Ann Intern Med 110: 916–921, 1989
Gonzalez-Barcena D, Ibarro-Olmos MA, Garcia-Carrasco F, Gutierrez-Samperio C, Comaru-Schally AM, Schally AV: Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 43: 313–317, 1989
Jackson IM, Matthews MJ, Diver JMJ: LHRH analogues in the treatment of cancer. Cancer Treatment Rev 16: 161–175, 1989
Santen RJ, Manni A, Harvey H: Gonadotropin-releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma. Breast Cancer Res Treat 7: 129–145, 1986
Miller WR: Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Molec Biol 37: 467–480, 1990
Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai RZ, Szepeshazi K, Radulovic S: Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies. J Steroid Biochem Molec Biol 37: 1061–1067, 1990
Redding TW, Schally AV: Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81: 248–252, 1984
Bramley TA, Menzies GS, Baird DT: Specificity of gonadotrophin-releasing hormone binding sites of the human corpus luteum: comparison with receptors of rat pituitary gland. J Endocrinol 108: 323–328, 1986
Currie AJ, Fraser HM, Sharpe RM: Human placental receptors for luteinizing hormone-releasing hormone. Biochem Biophys Res Commun 99: 332–338, 1981
Latouche J, Jordan D, Crumeyrolle-Arias M, Kopp N, Augendre-Ferrante B, Cedard L, Haour F: GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125: 1739–1741, 1989
Wiznitzer A, Marbach M, Hazum E, Insler V, Sharoni Y, Levy J: Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun 152: 1326–1331, 1988
Segal T, Levy J, Sharmis Y: GnRH analogs stimulate phospholipase C activity in mammary tumor membranes: Modulation by GTP. Mol Cell Endocrinol 53: 239–243, 1987
Neri C, Colomb E, Roux-Dosseto M, Martin PM: Distinct effects of gonadotropin-releasing hormone analogs and 4-hydroxytamoxifen on pS2 mRNA expression with respect to cell proliferation in MCF-7 breast cancer cells. Anticancer Res 11: 411–416, 1991
Seppälä M, Wahlström T: Identification of luteinizing hormone-releasing factor and alpha subunit of glycoprotein hormones in ductal carcinoma of the mammary gland. Int J Cancer 26: 267–268, 1980
Ciocca DR, Puy LA, Fasoli LC, Tello I, Aznar JC, Gago FE, Papa SI, Sonego R: Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat 15: 175–184, 1990
Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T: Effects of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinomain vivo. Anti Cancer Drugs 3: 109–116, 1992
EORTC Breast Cancer Cooperative Group: Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9: 379–381, 1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baumann, K.H., Kiesel, L., Kaufmann, M. et al. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Tr 25, 37–46 (1993). https://doi.org/10.1007/BF00662399
Issue Date:
DOI: https://doi.org/10.1007/BF00662399